These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DELAWARE
|
|
77-0024818
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
|
Common stock, $0.001 par value
|
|
CRUS
|
|
The NASDAQ Stock Market LLC
|
|
Large accelerated filer
þ
|
|
Accelerated filer
☐
|
|
Non-accelerated filer
☐
|
|
Smaller reporting company
☐
|
|
Emerging growth company
☐
|
|
PART I
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
Item 1A.
|
||
|
|
|
|
|
Item 1B.
|
||
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
PART II
|
|
|
|
|
|
|
|
Item 5.
|
||
|
|
|
|
|
Item 6.
|
||
|
|
|
|
|
Item 7.
|
||
|
|
|
|
|
Item 7A.
|
||
|
|
|
|
|
Item 8.
|
||
|
|
|
|
|
Item 9.
|
||
|
|
|
|
|
Item 9A.
|
||
|
|
|
|
|
PART III
|
|
|
|
|
|
|
|
Item 10.
|
||
|
|
|
|
|
Item 11.
|
||
|
|
|
|
|
Item 12.
|
||
|
|
|
|
|
Item 13.
|
||
|
|
|
|
|
Item 14.
|
||
|
|
|
|
|
PART IV
|
|
|
|
|
|
|
|
Item 15.
|
||
|
|
|
|
|
|
||
|
▪
|
most of our customers can stop incorporating our products into their own products with limited notice to us and suffer little or no penalty;
|
|
▪
|
our agreements with our customers typically do not require them to purchase a minimum quantity of our products;
|
|
▪
|
many of our customers have pre-existing or concurrent relationships with our current or potential competitors that may affect the customers’ decisions to purchase our products;
|
|
▪
|
many of our customers have sufficient resources to internally develop technology solutions and semiconductor components that could replace the products that we currently supply in our customers’ end products;
|
|
▪
|
our customers face intense competition from other manufacturers that do not use our products; and
|
|
▪
|
our customers regularly evaluate alternative sources of supply in order to diversify their supplier base, which increases their negotiating leverage with us and their ability to either obtain or dual source components from other suppliers.
|
|
▪
|
proper new product definition;
|
|
▪
|
timely completion of design and testing of new products;
|
|
▪
|
assisting our customers with integration of our components into their new products, including providing support from the concept stage through design, launch and production ramp;
|
|
▪
|
successfully developing and implementing the software necessary to integrate our products into our customers’ products;
|
|
▪
|
achievement of acceptable manufacturing yields;
|
|
▪
|
availability of wafer fabrication, assembly, and test capacity; and
|
|
▪
|
market acceptance of our products and the products of our customers.
|
|
▪
|
reduced margins;
|
|
▪
|
damage to our reputation;
|
|
▪
|
replacement costs for product warranty and support;
|
|
▪
|
payments to our customers related to recall claims, or the delivery of product replacements as part of a recall claim, as a result of various industry or business practices, contractual requirements, or in order to maintain good customer relationships;
|
|
▪
|
an adverse impact to our customer relationships by the occurrence of significant defects;
|
|
▪
|
a delay in recognition or loss of revenues, loss of market share, or failure to achieve market acceptance;
|
|
▪
|
writing off or reserving the value of inventory of such products; and
|
|
▪
|
a diversion of the attention of our engineering personnel from our product development efforts.
|
|
▪
|
a decline in demand for any of our more significant products;
|
|
▪
|
a decline in the average selling prices of our more significant products;
|
|
▪
|
failure of our products to achieve continued market acceptance;
|
|
▪
|
competitive products;
|
|
▪
|
new technological standards or changes to existing standards that we are unable to address with our products;
|
|
▪
|
manufacturing or supply issues that prevent us from meeting our customers’ demand for these products;
|
|
▪
|
a failure to release new products or enhanced versions of our existing products on a timely basis; and
|
|
▪
|
the failure of our new products to achieve market acceptance.
|
|
▪
|
insufficient capacity available to meet our demand;
|
|
▪
|
inadequate manufacturing yields and excessive costs;
|
|
▪
|
inability of these third parties to obtain an adequate supply of raw materials;
|
|
▪
|
difficulties selecting and integrating new subcontractors;
|
|
▪
|
limited warranties on products supplied to us;
|
|
▪
|
potential increases in prices; and
|
|
▪
|
increased exposure to potential misappropriation of our intellectual property.
|
|
▪
|
unexpected changes in government regulatory requirements;
|
|
▪
|
sales, VAT, or other indirect tax regulations and treaties and potential changes in regulations and treaties in the United States and in and between countries in which we manufacture or sell our products;
|
|
▪
|
changes to countries’ banking and credit requirements;
|
|
▪
|
changes in diplomatic and trade relationships;
|
|
▪
|
delays resulting from difficulties in obtaining export licenses for technology, particularly in China;
|
|
▪
|
any changes in U.S. trade policy, including potential adoption and expansion of trade restrictions, higher tariffs, or cross border taxation by the U.S. government involving other countries, particularly China, that might impact overall customer demand for our products or affect our ability to manufacture and/or sell our products overseas;
|
|
▪
|
tariffs and other barriers and restrictions, particularly in China;
|
|
▪
|
competition with non-U.S. companies or other domestic companies entering the non-U.S. markets in which we operate;
|
|
▪
|
longer sales and payment cycles;
|
|
▪
|
problems in collecting accounts receivable;
|
|
▪
|
changes to economic, social, or political conditions in countries such as China, where we have significant operations; and
|
|
▪
|
the burdens of complying with a variety of non-U.S. laws.
|
|
▪
|
difficulties in staffing and managing non-U.S. operations;
|
|
▪
|
failure in non-U.S. regions to adequately protect our intellectual property, patent, trademarks, copyrights, know-how, and other proprietary rights;
|
|
▪
|
global health conditions and potential natural disasters;
|
|
▪
|
political and economic instability in international regions;
|
|
▪
|
international currency controls and exchange rate fluctuations;
|
|
▪
|
vulnerability to terrorist groups targeting American interests abroad; and
|
|
▪
|
legal uncertainty regarding liability and compliance with non-U.S. laws and regulatory requirements.
|
|
▪
|
the volume and timing of orders received;
|
|
▪
|
changes in the mix of our products sold;
|
|
▪
|
market acceptance of our products and the products of our customers;
|
|
▪
|
excess or obsolete inventory;
|
|
▪
|
pricing pressures from competitors and key customers;
|
|
▪
|
our ability to introduce new products on a timely basis;
|
|
▪
|
the timing and extent of our research and development expenses;
|
|
▪
|
the failure to anticipate changing customer product requirements;
|
|
▪
|
disruption in the supply of wafers, assembly, or test services;
|
|
▪
|
reduction of manufacturing yields;
|
|
▪
|
certain production and other risks associated with using independent manufacturers, assembly houses, and testers; and
|
|
▪
|
product obsolescence, price erosion, competitive developments, and other competitive factors.
|
|
▪
|
the potential disruption of our ongoing business;
|
|
▪
|
unexpected costs or incurring unknown liabilities;
|
|
▪
|
the diversion of management resources from other strategic and operational issues;
|
|
▪
|
the inability to retain the employees of the acquired businesses;
|
|
▪
|
difficulties relating to integrating the operations and personnel of the acquired businesses;
|
|
▪
|
adverse effects on our existing customer relationships or the existing customer relationships of acquired businesses;
|
|
▪
|
the potential incompatibility of the acquired business or their business customers;
|
|
▪
|
adverse effects associated with entering into markets and acquiring technologies in areas in which we have little experience; and
|
|
▪
|
acquired intangible assets becoming impaired as a result of technological advancements or worse-than-expected performance of the acquired business.
|
|
▪
|
pay dividends on, repurchase or make distributions in respect of our capital stock or make other restricted payments;
|
|
▪
|
incur additional indebtedness or issue certain preferred shares;
|
|
▪
|
make certain investments;
|
|
▪
|
sell certain assets;
|
|
▪
|
create liens;
|
|
▪
|
consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and
|
|
▪
|
enter into certain transactions with our affiliates.
|
|
▪
|
actual or anticipated fluctuations in our operating results;
|
|
▪
|
announcements concerning our business or those of our competitors, customers, or suppliers;
|
|
▪
|
loss of a significant customer, or customers;
|
|
▪
|
changes in financial estimates by securities analysts or our failure to perform as anticipated by the analysts;
|
|
▪
|
news, commentary, and rumors emanating from the media relating to our customers, the industry, or us. These reports may be unrelated to the actual operating performance of the Company, and in some cases, may be potentially misleading or incorrect;
|
|
▪
|
announcements regarding technological innovations or new products by us or our competitors;
|
|
▪
|
announcements by us of significant acquisitions, strategic partnerships, joint ventures, or capital commitments;
|
|
▪
|
announcements by us of significant divestitures or sale of certain assets or intellectual property;
|
|
▪
|
litigation arising out of a wide variety of matters, including, among others, employment matters and intellectual property matters;
|
|
▪
|
departure of key personnel;
|
|
▪
|
a significant stockholder selling for any reason;
|
|
▪
|
general conditions in the IC industry; and
|
|
▪
|
general market conditions and interest rates.
|
|
▪
|
the inability of stockholders to call a special meeting of stockholders;
|
|
▪
|
a prohibition on stockholder action by written consent; and
|
|
▪
|
a requirement that stockholders provide advance notice of any stockholder nominations of directors or any proposal of new business to be considered at any meeting of stockholders.
|
|
▪
|
the possibility of environmental contamination and the costs associated with correcting any environmental problems;
|
|
▪
|
adverse changes in the value of these properties, due to interest rate changes, changes in the neighborhood in which the property is located, or other factors; and
|
|
▪
|
the risk of financial loss in excess of amounts covered by insurance, or uninsured risks, such as the loss caused by damage to the buildings as a result of fire, floods, or other natural disasters.
|
|
Design Centers
|
|
Sales Support Offices – International
|
|
Austin, Texas
|
|
Hong Kong, China
|
|
Mesa, Arizona
|
|
Shanghai, China
|
|
Salt Lake City, Utah
|
|
Shenzhen, China
|
|
Edinburgh, Scotland, United Kingdom
|
|
Tokyo, Japan
|
|
Newbury, England, United Kingdom
|
|
Singapore
|
|
London, England, United Kingdom
|
|
Seoul, South Korea
|
|
Melbourne, Australia
|
|
Taipei, Taiwan
|
|
Madrid, Spain
|
|
|
|
Monthly Period
|
Total Number of Shares Purchased
|
|
Average Price Paid Per Share
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
|
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)
|
||||||
|
December 30, 2018 -
January 26, 2019 |
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
January 27, 2019 -
February 23, 2019 |
258
|
|
|
38.69
|
|
|
258
|
|
|
40,003
|
|
||
|
February 24, 2019 -
March 30, 2019 |
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
|
Total
|
258
|
|
|
$
|
38.69
|
|
|
258
|
|
|
$
|
40,003
|
|
|
|
|
3/29/2014
|
|
3/28/2015
|
|
3/26/2016
|
|
3/25/2017
|
|
3/31/2018
|
|
3/30/2019
|
||||||
|
Cirrus Logic, Inc.
|
|
100.00
|
|
|
170.54
|
|
|
176.59
|
|
|
307.68
|
|
|
208.15
|
|
|
215.52
|
|
|
S&P 500 Index
|
|
100.00
|
|
|
113.23
|
|
|
114.28
|
|
|
134.41
|
|
|
154.48
|
|
|
169.15
|
|
|
S&P 500 Semiconductors Index
|
|
100.00
|
|
|
126.57
|
|
|
127.51
|
|
|
176.08
|
|
|
243.18
|
|
|
254.93
|
|
|
(1)
|
The graph assumes that $100 was invested in our common stock and in each index at the market close on
March 29, 2014
, and that all dividends were reinvested. No cash dividends were declared on our common stock during the periods presented.
|
|
(2)
|
Stockholder returns over the indicated period should not be considered indicative of future stockholder returns.
|
|
|
|
Fiscal Years
|
||||||||||||||||||
|
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
|
|
(1)
|
|
(1)
|
|
(1)
|
|
|
|
|
||||||||||
|
Net sales
|
|
$
|
1,185,524
|
|
|
$
|
1,532,186
|
|
|
$
|
1,538,940
|
|
|
$
|
1,169,251
|
|
|
$
|
916,568
|
|
|
Net income
|
|
89,991
|
|
|
161,995
|
|
|
261,209
|
|
|
123,630
|
|
|
55,178
|
|
|||||
|
Basic earnings per share
|
|
$
|
1.50
|
|
|
$
|
2.55
|
|
|
$
|
4.12
|
|
|
$
|
1.96
|
|
|
$
|
0.88
|
|
|
Diluted earnings per share
|
|
$
|
1.46
|
|
|
$
|
2.46
|
|
|
$
|
3.92
|
|
|
$
|
1.87
|
|
|
$
|
0.85
|
|
|
Financial position at year end:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Cash, cash equivalents, restricted investments and marketable securities
|
|
$
|
445,323
|
|
|
$
|
434,500
|
|
|
$
|
450,979
|
|
|
$
|
250,006
|
|
|
$
|
260,719
|
|
|
Total assets
|
|
1,352,640
|
|
|
1,430,117
|
|
|
1,413,470
|
|
|
1,181,883
|
|
|
1,148,778
|
|
|||||
|
Working capital
|
|
509,443
|
|
|
473,465
|
|
|
631,853
|
|
|
378,005
|
|
|
275,335
|
|
|||||
|
Long-term liabilities
|
|
96,860
|
|
|
128,180
|
|
|
117,703
|
|
|
194,276
|
|
|
215,429
|
|
|||||
|
Total stockholders’ equity
|
|
$
|
1,140,240
|
|
|
$
|
1,161,728
|
|
|
$
|
1,151,692
|
|
|
$
|
859,483
|
|
|
$
|
756,771
|
|
|
(1)
|
Refer to the consolidated financial statements and the Notes thereto contained in Item 8 of this Form 10-K for fiscal years
2019
,
2018
, and
2017
, for an expanded discussion of factors that materially affect the comparability of the information reflected in the selected consolidated financial data presented above.
|
|
▪
|
We report income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the financial reporting basis and tax basis of assets and liabilities, which are measured using the enacted tax laws and tax rates that will be in effect when the differences are expected to reverse. We assess the likelihood that the deferred tax assets will be realized. A valuation allowance is established against deferred tax assets to the extent the Company believes that it is more likely than not that the deferred tax assets will not be realized, taking into consideration the level of historical taxable income and projections for future taxable income over the periods in which the temporary differences are deductible.
|
|
▪
|
We recognize revenue upon the transfer of promised goods or services to customers, in an amount that reflects the consideration the Company expects to be entitled in exchange for those goods or services. See Note 2 - Summary of Significant Accounting Policies -
Revenue Recognition
of the Notes to Consolidated Financial Statements contained in Item 8 for discussion on the identification of the Company's performance obligations and determination of transaction price, including treatment of rebates, right of returns, warranties, price protection and stock rotation.
|
|
▪
|
Inventories are recorded at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. We write down inventories to net realizable value based on forecasted demand while taking into account product release schedules and product life cycles, which may drive management judgment. We also review and write down inventory, as appropriate, based on the age and condition of the inventory. Actual demand and market conditions may be different from those projected by management, which could have a material effect on our operating results and financial position. See Note 2 — Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements contained in Item 8.
|
|
▪
|
We evaluate the recoverability of property, plant, and equipment and intangible assets by testing for impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. An impairment loss is recognized in the event the carrying value of these assets exceeds the fair value of the applicable assets. Impairment evaluations involve management estimates of asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management, which could have a material effect on our operating results and financial position. See Note 6 — Intangibles, net and Goodwill of the Notes to Consolidated Financial Statements contained in Item 8.
|
|
▪
|
The Company evaluates goodwill and other intangible assets. Goodwill is recorded at the time of an acquisition and is calculated as the difference between the total consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired. The Company tests goodwill and other intangible assets for impairment on an annual basis or more frequently if the Company believes indicators of impairment exist. Impairment evaluations involve management’s assessment of qualitative factors to determine whether it is more likely than not that goodwill and other intangible assets are impaired. If management concludes from its assessment of qualitative factors that it is more likely than not that impairment exists, then a quantitative impairment test will be performed involving management estimates of asset useful lives and future cash flows. Significant management judgment is required in the forecasts of future operating results that are used in these evaluations. If our actual results, or the plans and estimates used in future impairment analyses, are lower than the original estimates used to assess the recoverability of these assets, we could incur additional impairment charges in a future period. The Company has recorded no goodwill impairments in fiscal years
2019
,
2018
, and
2017
. There were no material intangible asset impairments in fiscal years
2019
,
2018
, and
2017
.
|
|
▪
|
We are subject to the possibility of loss contingencies for various legal matters. See Note 12 — Legal Matters of the Notes to Consolidated Financial Statements contained in Item 8
.
We regularly evaluate current information available to us to determine whether any accruals should be made based on the status of the case, the results of the discovery process and other factors. If we ultimately determine that an accrual should be made for a legal matter, this accrual could have a material effect on our operating results and financial position and the ultimate outcome may be materially different than our estimate.
|
|
|
Balance at March 31, 2018
|
|
Impact from ASU 2014-09 Adoption
|
|
Balance at April 1, 2018
|
||||||
|
Financial statement line item:
|
|
|
|
|
|
||||||
|
Accounts receivable
|
$
|
100,801
|
|
|
$
|
5,539
|
|
|
$
|
106,340
|
|
|
Inventories
|
205,760
|
|
|
(391)
|
|
|
205,369
|
|
|||
|
Other current assets
|
13,877
|
|
|
391
|
|
|
14,268
|
|
|||
|
Other accrued liabilities
|
$
|
(12,657
|
)
|
|
$
|
(5,539
|
)
|
|
$
|
(18,196
|
)
|
|
|
|
Fiscal Years Ended
|
|||||||
|
|
|
March 30, 2019
|
|
March 31, 2018
|
|
March 25, 2017
|
|||
|
Net sales
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
Gross margin
|
|
50
|
%
|
|
50
|
%
|
|
49
|
%
|
|
Research and development
|
|
32
|
%
|
|
24
|
%
|
|
20
|
%
|
|
Selling, general and administrative
|
|
11
|
%
|
|
9
|
%
|
|
8
|
%
|
|
Gain on sale of assets
|
|
(1
|
)%
|
|
—
|
%
|
|
—
|
%
|
|
Asset impairment
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
Income from operations
|
|
8
|
%
|
|
17
|
%
|
|
21
|
%
|
|
Interest income
|
|
1
|
%
|
|
—
|
%
|
|
—
|
%
|
|
Interest expense
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
U.K. pension settlement
|
|
(1
|
)%
|
|
—
|
%
|
|
—
|
%
|
|
Other expense
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
Income before income taxes
|
|
8
|
%
|
|
17
|
%
|
|
21
|
%
|
|
Provision for income taxes
|
|
—
|
%
|
|
6
|
%
|
|
4
|
%
|
|
Net income
|
|
8
|
%
|
|
11
|
%
|
|
17
|
%
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Portable Products
|
|
$
|
1,032,049
|
|
|
$
|
1,363,876
|
|
|
$
|
1,373,848
|
|
|
Non-Portable and Other Products
|
|
153,475
|
|
|
168,310
|
|
|
165,092
|
|
|||
|
|
|
$
|
1,185,524
|
|
|
$
|
1,532,186
|
|
|
$
|
1,538,940
|
|
|
|
|
Payment due by period (in thousands)
|
||||||||||||||||||
|
|
|
< 1 year
|
|
1-3 years
|
|
3-5 years
|
|
> 5 years
|
|
Total
|
||||||||||
|
Facilities leases, net
|
|
$
|
14,343
|
|
|
$
|
26,647
|
|
|
$
|
24,025
|
|
|
$
|
35,388
|
|
|
$
|
100,403
|
|
|
Equipment and other commitments
|
|
144
|
|
|
278
|
|
|
239
|
|
|
222
|
|
|
883
|
|
|||||
|
Wafer purchase commitments
|
|
62,582
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
62,582
|
|
|||||
|
Assembly purchase commitments
|
|
1,397
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,397
|
|
|||||
|
Outside test purchase commitments
|
|
10,121
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10,121
|
|
|||||
|
Other purchase commitments
|
|
36,999
|
|
|
8,662
|
|
|
—
|
|
|
—
|
|
|
45,661
|
|
|||||
|
Interest on revolving line of credit (1)
|
|
455
|
|
|
935
|
|
|
—
|
|
|
—
|
|
|
1,390
|
|
|||||
|
Total
|
|
$
|
126,041
|
|
|
$
|
36,522
|
|
|
$
|
24,264
|
|
|
$
|
35,610
|
|
|
$
|
222,437
|
|
|
(1)
|
Our debt is subject to a variable interest rate based on LIBOR. The interest included in the table above is based on forecasted commitment fees.
|
|
|
|
March 30,
2019 |
|
March 31,
2018 |
||||
|
Assets
|
|
|
|
|
||||
|
Current assets:
|
|
|
|
|
||||
|
Cash and cash equivalents
|
|
$
|
216,172
|
|
|
$
|
235,604
|
|
|
Marketable securities
|
|
70,183
|
|
|
26,397
|
|
||
|
Accounts receivable, net
|
|
120,656
|
|
|
100,801
|
|
||
|
Inventories
|
|
164,733
|
|
|
205,760
|
|
||
|
Prepaid assets
|
|
30,794
|
|
|
31,235
|
|
||
|
Other current assets
|
|
22,445
|
|
|
13,877
|
|
||
|
Total current assets
|
|
624,983
|
|
|
613,674
|
|
||
|
Long-term marketable securities
|
|
158,968
|
|
|
172,499
|
|
||
|
Property and equipment, net
|
|
186,185
|
|
|
191,154
|
|
||
|
Intangibles, net
|
|
67,847
|
|
|
111,547
|
|
||
|
Goodwill
|
|
286,241
|
|
|
288,718
|
|
||
|
Deferred tax assets
|
|
8,727
|
|
|
14,716
|
|
||
|
Other assets
|
|
19,689
|
|
|
37,809
|
|
||
|
Total assets
|
|
$
|
1,352,640
|
|
|
$
|
1,430,117
|
|
|
Liabilities and Stockholders’ Equity
|
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
|
||||
|
Accounts payable
|
|
$
|
48,398
|
|
|
$
|
69,850
|
|
|
Accrued salaries and benefits
|
|
29,289
|
|
|
35,721
|
|
||
|
Software license agreements
|
|
21,514
|
|
|
21,981
|
|
||
|
Other accrued liabilities
|
|
16,339
|
|
|
12,657
|
|
||
|
Total current liabilities
|
|
115,540
|
|
|
140,209
|
|
||
|
Long-term liabilities:
|
|
|
|
|
||||
|
Software license agreements
|
|
8,662
|
|
|
27,765
|
|
||
|
Non-current income taxes
|
|
78,309
|
|
|
92,753
|
|
||
|
Other long-term liabilities
|
|
9,889
|
|
|
7,662
|
|
||
|
Total long-term liabilities
|
|
96,860
|
|
|
128,180
|
|
||
|
Stockholders’ equity:
|
|
|
|
|
||||
|
Preferred stock, 5.0 million shares authorized but unissued
|
|
—
|
|
|
—
|
|
||
|
Common stock, $0.001 par value, 280,000 shares authorized, 58,954 shares and 61,960 shares issued and outstanding at March 30, 2019 and March 31, 2018, respectively
|
|
59
|
|
|
62
|
|
||
|
Additional paid-in capital
|
|
1,363,677
|
|
|
1,312,372
|
|
||
|
Accumulated deficit
|
|
(222,430
|
)
|
|
(139,345
|
)
|
||
|
Accumulated other comprehensive loss
|
|
(1,066
|
)
|
|
(11,361
|
)
|
||
|
Total stockholders’ equity
|
|
1,140,240
|
|
|
1,161,728
|
|
||
|
Total liabilities and stockholders’ equity
|
|
$
|
1,352,640
|
|
|
$
|
1,430,117
|
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Net sales
|
|
$
|
1,185,524
|
|
|
$
|
1,532,186
|
|
|
$
|
1,538,940
|
|
|
Cost of sales
|
|
588,027
|
|
|
771,470
|
|
|
781,125
|
|
|||
|
Gross profit
|
|
597,497
|
|
|
760,716
|
|
|
757,815
|
|
|||
|
Operating expenses
|
|
|
|
|
|
|
||||||
|
Research and development
|
|
375,139
|
|
|
366,444
|
|
|
303,658
|
|
|||
|
Selling, general and administrative
|
|
126,502
|
|
|
131,811
|
|
|
127,265
|
|
|||
|
Gain on sale of assets
|
|
(4,913
|
)
|
|
—
|
|
|
—
|
|
|||
|
Asset impairment
|
|
—
|
|
|
—
|
|
|
9,842
|
|
|||
|
Total operating expenses
|
|
496,728
|
|
|
498,255
|
|
|
440,765
|
|
|||
|
Income from operations
|
|
100,769
|
|
|
262,461
|
|
|
317,050
|
|
|||
|
Interest income
|
|
8,017
|
|
|
4,762
|
|
|
1,676
|
|
|||
|
Interest expense
|
|
(1,057
|
)
|
|
(1,153
|
)
|
|
(3,600
|
)
|
|||
|
U.K. pension settlement
|
|
(13,768
|
)
|
|
—
|
|
|
—
|
|
|||
|
Other expense
|
|
(217
|
)
|
|
(971
|
)
|
|
(79
|
)
|
|||
|
Income before income taxes
|
|
93,744
|
|
|
265,099
|
|
|
315,047
|
|
|||
|
Provision for income taxes
|
|
3,753
|
|
|
103,104
|
|
|
53,838
|
|
|||
|
Net income
|
|
89,991
|
|
|
161,995
|
|
|
261,209
|
|
|||
|
Basic earnings per share
|
|
$
|
1.50
|
|
|
$
|
2.55
|
|
|
$
|
4.12
|
|
|
Diluted earnings per share
|
|
$
|
1.46
|
|
|
$
|
2.46
|
|
|
$
|
3.92
|
|
|
Basic weighted average common shares outstanding
|
|
60,116
|
|
|
63,407
|
|
|
63,329
|
|
|||
|
Diluted weighted average common shares outstanding
|
|
61,583
|
|
|
65,951
|
|
|
66,561
|
|
|||
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Net income
|
|
$
|
89,991
|
|
|
$
|
161,995
|
|
|
$
|
261,209
|
|
|
Other comprehensive income (loss), before tax
|
|
|
|
|
|
|
||||||
|
Foreign currency translation gain (loss)
|
|
(3,125
|
)
|
|
2,791
|
|
|
(826
|
)
|
|||
|
Unrealized gain (loss) on marketable securities
|
|
2,823
|
|
|
(2,380
|
)
|
|
47
|
|
|||
|
U.K. pension settlement
|
|
13,814
|
|
|
—
|
|
|
—
|
|
|||
|
Actuarial loss on defined benefit pension plan
|
|
—
|
|
|
(14,729
|
)
|
|
(79
|
)
|
|||
|
Reclassification of actuarial gain to net income
|
|
—
|
|
|
—
|
|
|
(89
|
)
|
|||
|
Benefit (provision) for income taxes
|
|
(3,217
|
)
|
|
3,530
|
|
|
42
|
|
|||
|
Comprehensive income
|
|
$
|
100,286
|
|
|
$
|
151,207
|
|
|
$
|
260,304
|
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
|
Net income
|
|
$
|
89,991
|
|
|
$
|
161,995
|
|
|
$
|
261,209
|
|
|
Adjustments to net cash provided by operating activities:
|
|
|
|
|
|
|
||||||
|
Depreciation and amortization
|
|
79,826
|
|
|
81,399
|
|
|
63,433
|
|
|||
|
Stock-based compensation expense
|
|
49,689
|
|
|
48,741
|
|
|
39,593
|
|
|||
|
Deferred income taxes
|
|
1,717
|
|
|
11,646
|
|
|
10,885
|
|
|||
|
(Gain) loss on retirement or write-off of long-lived assets
|
|
(2,713
|
)
|
|
626
|
|
|
10,387
|
|
|||
|
Charges (payments) for defined benefit pension plan
|
|
11,189
|
|
|
(10,929
|
)
|
|
116
|
|
|||
|
Other non-cash charges
|
|
429
|
|
|
(3,864
|
)
|
|
8,980
|
|
|||
|
Net change in operating assets and liabilities:
|
|
|
|
|
|
|
||||||
|
Accounts receivable, net
|
|
(14,316
|
)
|
|
19,173
|
|
|
(31,442
|
)
|
|||
|
Inventories
|
|
40,636
|
|
|
(37,865
|
)
|
|
(25,880
|
)
|
|||
|
Other assets
|
|
965
|
|
|
16,824
|
|
|
575
|
|
|||
|
Accounts payable
|
|
(21,965
|
)
|
|
143
|
|
|
1,772
|
|
|||
|
Accrued salaries and benefits
|
|
(6,432
|
)
|
|
(4,469
|
)
|
|
18,951
|
|
|||
|
Income taxes payable
|
|
(7,974
|
)
|
|
22,983
|
|
|
10,969
|
|
|||
|
Other accrued liabilities
|
|
(14,348
|
)
|
|
12,308
|
|
|
203
|
|
|||
|
Net cash provided by operating activities
|
|
206,694
|
|
|
318,711
|
|
|
369,751
|
|
|||
|
Cash flows from investing activities:
|
|
|
|
|
|
|
||||||
|
Maturities and sales of available-for-sale marketable securities
|
|
70,840
|
|
|
138,221
|
|
|
212,863
|
|
|||
|
Purchases of available-for-sale marketable securities
|
|
(98,864
|
)
|
|
(238,434
|
)
|
|
(231,432
|
)
|
|||
|
Purchases of property, equipment and software
|
|
(31,615
|
)
|
|
(55,180
|
)
|
|
(41,849
|
)
|
|||
|
Investments in technology
|
|
(4,143
|
)
|
|
(29,323
|
)
|
|
(9,447
|
)
|
|||
|
Proceeds from the sale of assets
|
|
9,120
|
|
|
—
|
|
|
—
|
|
|||
|
Net cash used in investing activities
|
|
(54,662
|
)
|
|
(184,716
|
)
|
|
(69,865
|
)
|
|||
|
Cash flows from financing activities:
|
|
|
|
|
|
|
||||||
|
Principal payments on long-term revolver
|
|
—
|
|
|
(60,000
|
)
|
|
(100,439
|
)
|
|||
|
Debt issuance costs
|
|
—
|
|
|
—
|
|
|
(2,152
|
)
|
|||
|
Payments on capital lease agreements
|
|
—
|
|
|
—
|
|
|
(699
|
)
|
|||
|
Issuance of common stock, net of shares withheld for taxes
|
|
1,616
|
|
|
4,417
|
|
|
16,518
|
|
|||
|
Repurchase of stock to satisfy employee tax withholding obligations
|
|
(13,083
|
)
|
|
(17,806
|
)
|
|
(14,089
|
)
|
|||
|
Repurchase and retirement of common stock
|
|
(159,997
|
)
|
|
(175,776
|
)
|
|
(15,439
|
)
|
|||
|
Contingent consideration payments
|
|
—
|
|
|
(392
|
)
|
|
(1,213
|
)
|
|||
|
Net cash used in financing activities
|
|
(171,464
|
)
|
|
(249,557
|
)
|
|
(117,513
|
)
|
|||
|
Net (decrease) increase in cash and cash equivalents
|
|
(19,432
|
)
|
|
(115,562
|
)
|
|
182,373
|
|
|||
|
Cash and cash equivalents at beginning of period
|
|
235,604
|
|
|
351,166
|
|
|
168,793
|
|
|||
|
Cash and cash equivalents at end of period
|
|
$
|
216,172
|
|
|
$
|
235,604
|
|
|
$
|
351,166
|
|
|
Supplemental disclosures of cash flow information
|
|
|
|
|
|
|
||||||
|
Cash payments during the year for:
|
|
|
|
|
|
|
||||||
|
Income taxes
|
|
$
|
20,617
|
|
|
$
|
34,385
|
|
|
$
|
8,001
|
|
|
Interest
|
|
612
|
|
|
835
|
|
|
2,947
|
|
|||
|
|
|
Common Stock
|
|
Additional
Paid-In Capital |
|
Accumulated
Deficit |
|
Accumulated
Other Comprehensive Income / (Loss) |
|
Total
|
|||||||||||||
|
|
|
Shares
|
|
Amount
|
|
||||||||||||||||||
|
Balance, March 26, 2016
|
|
62,630
|
|
|
$
|
63
|
|
|
$
|
1,203,433
|
|
|
$
|
(344,345
|
)
|
|
$
|
332
|
|
|
$
|
859,483
|
|
|
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
261,209
|
|
|
—
|
|
|
261,209
|
|
|||||
|
Change in unrealized gain (loss) on marketable securities, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
31
|
|
|
31
|
|
|||||
|
Change in defined benefit pension plan liability, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(110
|
)
|
|
(110
|
)
|
|||||
|
Change in foreign currency translation adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(826
|
)
|
|
(826
|
)
|
|||||
|
Issuance of stock under stock option plans and other, net of shares withheld for employee taxes
|
|
2,145
|
|
|
2
|
|
|
16,516
|
|
|
(14,089
|
)
|
|
—
|
|
|
2,429
|
|
|||||
|
Cumulative effect of adoption of ASU 2016-09
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5,649
|
|
|
—
|
|
|
5,649
|
|
|||||
|
Repurchase and retirement of common stock
|
|
(480
|
)
|
|
(1
|
)
|
|
—
|
|
|
(15,438
|
)
|
|
—
|
|
|
(15,439
|
)
|
|||||
|
Amortization of deferred stock compensation
|
|
—
|
|
|
—
|
|
|
39,593
|
|
|
—
|
|
|
—
|
|
|
39,593
|
|
|||||
|
Excess tax benefit from employee stock awards
|
|
—
|
|
|
—
|
|
|
(327
|
)
|
|
—
|
|
|
—
|
|
|
(327
|
)
|
|||||
|
Balance, March 25, 2017
|
|
64,295
|
|
|
64
|
|
|
1,259,215
|
|
|
(107,014
|
)
|
|
(573
|
)
|
|
1,151,692
|
|
|||||
|
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
161,995
|
|
|
—
|
|
|
161,995
|
|
|||||
|
Change in unrealized gain (loss) on marketable securities, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,630
|
)
|
|
(1,630
|
)
|
|||||
|
Change in defined benefit pension plan liability, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(11,949
|
)
|
|
(11,949
|
)
|
|||||
|
Change in foreign currency translation adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,791
|
|
|
2,791
|
|
|||||
|
Issuance of stock under stock option plans and other, net of shares withheld for employee taxes
|
|
1,054
|
|
|
1
|
|
|
4,416
|
|
|
(17,806
|
)
|
|
—
|
|
|
(13,389
|
)
|
|||||
|
Cumulative effect of adoption of ASU 2016-16
|
|
—
|
|
|
—
|
|
|
|
|
|
(747
|
)
|
|
—
|
|
|
(747
|
)
|
|||||
|
Repurchase and retirement of common stock
|
|
(3,389
|
)
|
|
(3
|
)
|
|
—
|
|
|
(175,773
|
)
|
|
—
|
|
|
(175,776
|
)
|
|||||
|
Amortization of deferred stock compensation
|
|
—
|
|
|
—
|
|
|
48,741
|
|
|
—
|
|
|
—
|
|
|
48,741
|
|
|||||
|
Balance, March 31, 2018
|
|
61,960
|
|
|
62
|
|
|
1,312,372
|
|
|
(139,345
|
)
|
|
(11,361
|
)
|
|
1,161,728
|
|
|||||
|
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
89,991
|
|
|
—
|
|
|
89,991
|
|
|||||
|
Change in unrealized gain (loss) on marketable securities, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,231
|
|
|
2,231
|
|
|||||
|
Change in defined benefit pension plan liability, net of tax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11,189
|
|
|
11,189
|
|
|||||
|
Change in foreign currency translation adjustments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3,125
|
)
|
|
(3,125
|
)
|
|||||
|
Issuance of stock under stock option plans and other, net of shares withheld for employee taxes
|
|
964
|
|
|
1
|
|
|
1,616
|
|
|
(13,083
|
)
|
|
—
|
|
|
(11,466
|
)
|
|||||
|
Repurchase and retirement of common stock
|
|
(3,970
|
)
|
|
(4
|
)
|
|
—
|
|
|
(159,993
|
)
|
|
—
|
|
|
(159,997
|
)
|
|||||
|
Amortization of deferred stock compensation
|
|
—
|
|
|
—
|
|
|
49,689
|
|
|
—
|
|
|
—
|
|
|
49,689
|
|
|||||
|
Balance, March 30, 2019
|
|
58,954
|
|
|
$
|
59
|
|
|
$
|
1,363,677
|
|
|
$
|
(222,430
|
)
|
|
$
|
(1,066
|
)
|
|
$
|
1,140,240
|
|
|
|
March 30, 2019
|
|
March 31, 2018
|
||||
|
Work in process
|
$
|
80,100
|
|
|
$
|
97,138
|
|
|
Finished goods
|
84,633
|
|
|
108,622
|
|
||
|
|
$
|
164,733
|
|
|
$
|
205,760
|
|
|
|
March 30, 2019
|
|
March 31, 2018
|
||||
|
Land
|
$
|
23,853
|
|
|
$
|
26,379
|
|
|
Buildings
|
63,172
|
|
|
71,354
|
|
||
|
Furniture and fixtures
|
22,762
|
|
|
22,138
|
|
||
|
Leasehold improvements
|
45,286
|
|
|
35,569
|
|
||
|
Machinery and equipment
|
157,994
|
|
|
143,509
|
|
||
|
Capitalized software
|
25,763
|
|
|
25,949
|
|
||
|
Construction in progress
|
3,689
|
|
|
6,086
|
|
||
|
Total property, plant and equipment
|
342,519
|
|
|
330,984
|
|
||
|
Less: Accumulated depreciation and amortization
|
(156,334
|
)
|
|
(139,830
|
)
|
||
|
Property, plant and equipment, net
|
$
|
186,185
|
|
|
$
|
191,154
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
March 30, 2019
|
|
March 31, 2018
|
|
March 25, 2017
|
||||||
|
Numerator:
|
|
|
|
|
|
||||||
|
Net income
|
$
|
89,991
|
|
|
$
|
161,995
|
|
|
$
|
261,209
|
|
|
Denominator:
|
|
|
|
|
|
||||||
|
Weighted average shares outstanding
|
60,116
|
|
|
63,407
|
|
|
63,329
|
|
|||
|
Effect of dilutive securities
|
1,467
|
|
|
2,544
|
|
|
3,232
|
|
|||
|
Weighted average diluted shares
|
61,583
|
|
|
65,951
|
|
|
66,561
|
|
|||
|
Basic earnings per share
|
$
|
1.50
|
|
|
$
|
2.55
|
|
|
$
|
4.12
|
|
|
Diluted earnings per share
|
$
|
1.46
|
|
|
$
|
2.46
|
|
|
$
|
3.92
|
|
|
|
Balance at March 31, 2018
|
|
Impact from ASU 2014-09 Adoption
|
|
Balance at April 1, 2018
|
||||||
|
Financial statement line item:
|
|
|
|
|
|
||||||
|
Accounts receivable
|
$
|
100,801
|
|
|
$
|
5,539
|
|
|
$
|
106,340
|
|
|
Inventories
|
205,760
|
|
|
(391)
|
|
|
205,369
|
|
|||
|
Other current assets
|
13,877
|
|
|
391
|
|
|
14,268
|
|
|||
|
Other accrued liabilities
|
$
|
(12,657
|
)
|
|
$
|
(5,539
|
)
|
|
$
|
(18,196
|
)
|
|
As of March 30, 2019
|
Amortized
Cost
|
|
Gross Unrealized
Gains
|
|
Gross Unrealized
Losses
|
|
Estimated Fair Value
(Net Carrying Amount)
|
||||||||
|
Corporate debt securities
|
$
|
215,098
|
|
|
$
|
1,027
|
|
|
$
|
(600
|
)
|
|
$
|
215,525
|
|
|
Non-US government securities
|
13,209
|
|
|
8
|
|
|
(40
|
)
|
|
13,177
|
|
||||
|
Agency discount notes
|
450
|
|
|
—
|
|
|
(1
|
)
|
|
449
|
|
||||
|
Total securities
|
$
|
228,757
|
|
|
$
|
1,035
|
|
|
$
|
(641
|
)
|
|
$
|
229,151
|
|
|
As of March 31, 2018
|
Amortized
Cost
|
|
Gross Unrealized
Gains
|
|
Gross Unrealized
Losses
|
|
Estimated Fair Value
(Net Carrying Amount)
|
||||||||
|
Corporate debt securities
|
$
|
185,636
|
|
|
$
|
4
|
|
|
$
|
(2,318
|
)
|
|
$
|
183,322
|
|
|
Non-US government securities
|
14,730
|
|
|
—
|
|
|
(111
|
)
|
|
14,619
|
|
||||
|
Certificates of deposit
|
500
|
|
|
—
|
|
|
—
|
|
|
500
|
|
||||
|
Agency discount notes
|
459
|
|
|
—
|
|
|
(4
|
)
|
|
455
|
|
||||
|
Total securities
|
$
|
201,325
|
|
|
$
|
4
|
|
|
$
|
(2,433
|
)
|
|
$
|
198,896
|
|
|
|
March 30, 2019
|
|
March 31, 2018
|
||||||||||||
|
|
Amortized
Cost
|
|
Estimated
Fair Value
|
|
Amortized
Cost
|
|
Estimated
Fair Value
|
||||||||
|
Within 1 year
|
$
|
70,490
|
|
|
$
|
70,183
|
|
|
$
|
26,560
|
|
|
$
|
26,397
|
|
|
After 1 year
|
158,267
|
|
|
158,968
|
|
|
174,765
|
|
|
172,499
|
|
||||
|
Total
|
$
|
228,757
|
|
|
$
|
229,151
|
|
|
$
|
201,325
|
|
|
$
|
198,896
|
|
|
▪
|
Level 1 — Quoted prices in active markets for identical assets or liabilities.
|
|
▪
|
Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
|
|
▪
|
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
|
|
Quoted Prices
in Active
Markets for
Identical
Assets
Level 1
|
|
Significant
Other
Observable
Inputs
Level 2
|
|
Significant
Unobservable
Inputs
Level 3
|
|
Total
|
||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Cash equivalents
|
|
|
|
|
|
|
|
||||||||
|
Money market funds
|
$
|
216,172
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
216,172
|
|
|
Available-for-sale securities
|
|
|
|
|
|
|
|
||||||||
|
Corporate debt securities
|
$
|
—
|
|
|
$
|
215,525
|
|
|
$
|
—
|
|
|
$
|
215,525
|
|
|
Non-US government securities
|
—
|
|
|
13,177
|
|
|
—
|
|
|
13,177
|
|
||||
|
Agency discount notes
|
—
|
|
|
449
|
|
|
—
|
|
|
449
|
|
||||
|
|
$
|
—
|
|
|
$
|
229,151
|
|
|
$
|
—
|
|
|
$
|
229,151
|
|
|
|
Quoted Prices
in Active
Markets for
Identical
Assets
Level 1
|
|
Significant
Other
Observable
Inputs
Level 2
|
|
Significant
Unobservable
Inputs
Level 3
|
|
Total
|
||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Cash equivalents
|
|
|
|
|
|
|
|
||||||||
|
Money market funds
|
$
|
211,891
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
211,891
|
|
|
Available-for-sale securities
|
|
|
|
|
|
|
|
||||||||
|
Corporate debt securities
|
$
|
—
|
|
|
$
|
183,322
|
|
|
$
|
—
|
|
|
$
|
183,322
|
|
|
Non-US government securities
|
—
|
|
|
14,619
|
|
|
—
|
|
|
14,619
|
|
||||
|
Certificates of deposit
|
—
|
|
|
500
|
|
|
—
|
|
|
500
|
|
||||
|
Agency discount notes
|
—
|
|
|
455
|
|
|
—
|
|
|
455
|
|
||||
|
|
$
|
—
|
|
|
$
|
198,896
|
|
|
$
|
—
|
|
|
$
|
198,896
|
|
|
|
Maximum Value if
Milestones Achieved
(in thousands)
|
|
Estimated
Discount
Rate (%)
|
|
Fair Value
(in thousands)
|
||
|
Tranche B — 30 month earn out period
|
5,000
|
|
|
7.7
|
|
—
|
|
|
|
|
Fiscal Year Ended
|
||
|
|
|
March 31, 2018
|
||
|
|
|
(in thousands)
|
||
|
Beginning balance
|
|
$
|
4,695
|
|
|
Adjustment to estimates (research and development expense)
|
|
(4,328
|
)
|
|
|
Payout of Tranche B contingent consideration
|
|
(392
|
)
|
|
|
Fair value charge recognized in earnings (research and development expense)
|
|
25
|
|
|
|
Ending balance
|
|
$
|
—
|
|
|
|
|
March 30, 2019
|
|
March 31, 2018
|
||||
|
Gross accounts receivable
|
|
$
|
120,926
|
|
|
$
|
101,004
|
|
|
Allowance for doubtful accounts
|
|
(270
|
)
|
|
(203
|
)
|
||
|
Accounts receivable, net
|
|
$
|
120,656
|
|
|
$
|
100,801
|
|
|
Balance, March 26, 2016
|
$
|
(475
|
)
|
|
Bad debt expense, net of recoveries
|
41
|
|
|
|
Balance, March 25, 2017
|
(434
|
)
|
|
|
Bad debt expense, net of recoveries
|
231
|
|
|
|
Balance, March 31, 2018
|
(203
|
)
|
|
|
Bad debt expense, net or recoveries
|
(67
|
)
|
|
|
Balance, March 30, 2019
|
$
|
(270
|
)
|
|
|
|
March 30, 2019
|
|
March 31, 2018
|
||||||||||||
|
Intangible Category / Weighted-Average Amortization
period (in years)
|
|
Gross
Amount
|
|
Accumulated
Amortization
|
|
Gross
Amount
|
|
Accumulated
Amortization
|
||||||||
|
Core technology (a)
|
|
$
|
1,390
|
|
|
$
|
(1,390
|
)
|
|
$
|
1,390
|
|
|
$
|
(1,390
|
)
|
|
License agreement (a)
|
|
440
|
|
|
(440
|
)
|
|
440
|
|
|
(440
|
)
|
||||
|
Existing technology (6.3)
|
|
117,976
|
|
|
(94,136
|
)
|
|
117,976
|
|
|
(75,048
|
)
|
||||
|
In-process research & development (“IPR&D”) (7.3)
|
|
97,972
|
|
|
(69,794
|
)
|
|
97,972
|
|
|
(49,556
|
)
|
||||
|
Trademarks and tradename (10.0)
|
|
3,037
|
|
|
(2,461
|
)
|
|
3,037
|
|
|
(2,333
|
)
|
||||
|
Customer relationships (10.0)
|
|
15,381
|
|
|
(7,270
|
)
|
|
15,381
|
|
|
(5,732
|
)
|
||||
|
Backlog (a)
|
|
220
|
|
|
(220
|
)
|
|
220
|
|
|
(220
|
)
|
||||
|
Non-compete agreements (a)
|
|
470
|
|
|
(470
|
)
|
|
470
|
|
|
(470
|
)
|
||||
|
Technology licenses (3.0)
|
|
28,336
|
|
|
(21,194
|
)
|
|
28,063
|
|
|
(18,213
|
)
|
||||
|
Total
|
|
$
|
265,222
|
|
|
$
|
(197,375
|
)
|
|
$
|
264,949
|
|
|
$
|
(153,402
|
)
|
|
(a)
|
Intangible assets are fully amortized.
|
|
For the year ended March 28, 2020
|
$
|
28,443
|
|
|
For the year ended March 27, 2021
|
$
|
17,750
|
|
|
For the year ended March 26, 2022
|
$
|
12,755
|
|
|
For the year ended March 25, 2023
|
$
|
6,663
|
|
|
For the year ended March 30, 2024
|
$
|
1,695
|
|
|
Thereafter
|
$
|
541
|
|
|
|
Year Ended
|
||||||||||
|
|
March 30,
|
|
March 31,
|
|
March 25,
|
||||||
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Non-United States
|
$
|
1,159,342
|
|
|
$
|
1,498,454
|
|
|
$
|
1,502,916
|
|
|
United States
|
26,182
|
|
|
33,732
|
|
|
36,024
|
|
|||
|
|
$
|
1,185,524
|
|
|
$
|
1,532,186
|
|
|
$
|
1,538,940
|
|
|
|
|
March 30,
2019 |
|
March 31,
2018 |
||||
|
Change in benefit obligation:
|
|
|
|
|
||||
|
Beginning balance
|
|
$
|
40,601
|
|
|
$
|
21,123
|
|
|
Interest cost
|
|
—
|
|
|
651
|
|
||
|
Plan settlements
|
|
(40,601
|
)
|
|
—
|
|
||
|
Benefits paid and expenses
|
|
—
|
|
|
(312
|
)
|
||
|
Change in foreign currency exchange rate
|
|
—
|
|
|
2,869
|
|
||
|
Actuarial loss
|
|
—
|
|
|
16,270
|
|
||
|
Total benefit obligation ending balance
|
|
—
|
|
|
40,601
|
|
||
|
Change in plan assets:
|
|
|
|
|
||||
|
Beginning balance
|
|
40,601
|
|
|
22,143
|
|
||
|
Actual return on plan assets
|
|
—
|
|
|
2,700
|
|
||
|
Employer contributions
|
|
—
|
|
|
12,877
|
|
||
|
Plan settlements
|
|
(40,601
|
)
|
|
—
|
|
||
|
Change in foreign currency exchange rate
|
|
—
|
|
|
3,193
|
|
||
|
Benefits paid and expenses
|
|
—
|
|
|
(312
|
)
|
||
|
Fair value of plan assets ending balance
|
|
—
|
|
|
40,601
|
|
||
|
Funded status of Scheme at end of year
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Expenses
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Interest cost
|
|
—
|
|
|
651
|
|
|
759
|
|
|||
|
Expected return on plan assets
|
|
—
|
|
|
(1,159
|
)
|
|
(1,126
|
)
|
|||
|
Settlement loss
|
|
—
|
|
|
—
|
|
|
1,063
|
|
|||
|
Amortization of actuarial gain
|
|
—
|
|
|
—
|
|
|
(89
|
)
|
|||
|
|
|
$
|
—
|
|
|
$
|
(508
|
)
|
|
$
|
607
|
|
|
|
|
2019
|
|
2018
|
|
2017
|
||
|
Discount rate
|
|
n/a
|
|
2.70
|
%
|
|
3.60
|
%
|
|
Expected long-term return on plan assets
|
|
n/a
|
|
4.23
|
%
|
|
4.93
|
%
|
|
|
|
Quoted Prices
in Active Markets for Identical Assets Level 1 |
|
Significant
Other Observable Inputs Level 2 |
|
Significant
Unobservable Inputs Level 3 |
|
Total
|
||||||||
|
Plan Assets:
|
|
|
|
|
|
|
|
|
||||||||
|
Insurance contracts
|
|
$
|
—
|
|
|
$
|
40,601
|
|
|
$
|
—
|
|
|
$
|
40,601
|
|
|
|
Shares
|
|
|
|
Available for
|
|
|
|
Grant
|
|
|
Balance, March 26, 2016
|
6,287
|
|
|
Shares added
|
—
|
|
|
Granted
|
(1,719
|
)
|
|
Forfeited
|
124
|
|
|
Balance, March 25, 2017
|
4,692
|
|
|
Shares added
|
—
|
|
|
Granted
|
(1,755
|
)
|
|
Forfeited
|
128
|
|
|
Balance, March 31, 2018
|
3,065
|
|
|
Shares added
|
2,509
|
|
|
Granted
|
(2,371
|
)
|
|
Forfeited
|
120
|
|
|
Balance, March 30, 2019
|
3,323
|
|
|
|
|
Fiscal Year
|
||||||||||
|
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Cost of sales
|
|
$
|
877
|
|
|
$
|
1,474
|
|
|
$
|
1,071
|
|
|
Research and development
|
|
29,115
|
|
|
26,137
|
|
|
21,186
|
|
|||
|
Sales, general and administrative
|
|
19,697
|
|
|
21,130
|
|
|
17,336
|
|
|||
|
Effect on pre-tax income
|
|
49,689
|
|
|
48,741
|
|
|
39,593
|
|
|||
|
Income Tax Benefit
|
|
(5,748
|
)
|
|
(5,953
|
)
|
|
(12,482
|
)
|
|||
|
Total stock-based compensation expense (net of taxes)
|
|
43,941
|
|
|
42,788
|
|
|
27,111
|
|
|||
|
Stock-based compensation effects on basic earnings per share
|
|
$
|
0.73
|
|
|
$
|
0.67
|
|
|
$
|
0.43
|
|
|
Stock-based compensation effects on diluted earnings per share
|
|
0.71
|
|
|
0.65
|
|
|
0.41
|
|
|||
|
|
|
March 30, 2019
|
|
March 31, 2018
|
|
March 25, 2017
|
||
|
Expected stock price volatility
|
|
38.00-38.14 %
|
|
37.36
|
%
|
|
47.66
|
%
|
|
Risk-free interest rate
|
|
2.57-2.94 %
|
|
1.67
|
%
|
|
1.13
|
%
|
|
Expected term (in years)
|
|
3.12-3.73
|
|
3.03
|
|
|
2.79
|
|
|
|
|
Outstanding Options
|
|||||
|
|
|
Number
|
|
Weighted
Average Exercise Price |
|||
|
Balance, March 26, 2016
|
|
2,925
|
|
|
$
|
17.96
|
|
|
Options granted
|
|
215
|
|
|
54.65
|
|
|
|
Options exercised
|
|
(1,382
|
)
|
|
11.87
|
|
|
|
Options forfeited
|
|
—
|
|
|
—
|
|
|
|
Options expired
|
|
—
|
|
|
—
|
|
|
|
Balance, March 25, 2017
|
|
1,758
|
|
|
$
|
27.25
|
|
|
Options granted
|
|
216
|
|
|
55.72
|
|
|
|
Options exercised
|
|
(234
|
)
|
|
18.84
|
|
|
|
Options forfeited
|
|
—
|
|
|
—
|
|
|
|
Options expired
|
|
—
|
|
|
—
|
|
|
|
Balance, March 31, 2018
|
|
1,740
|
|
|
$
|
31.91
|
|
|
Options granted
|
|
280
|
|
|
40.41
|
|
|
|
Options exercised
|
|
(108
|
)
|
|
15.03
|
|
|
|
Options forfeited
|
|
(38
|
)
|
|
49.62
|
|
|
|
Options expired
|
|
(9
|
)
|
|
55.01
|
|
|
|
Balance, March 30, 2019
|
|
1,865
|
|
|
$
|
33.68
|
|
|
|
|
Number of
Options |
|
Weighted
Average Exercise price |
|
Weighted Average
Remaining Contractual Term (years) |
|
Aggregate
Intrinsic Value |
|||||
|
Vested and expected to vest
|
|
1,858
|
|
|
$
|
33.64
|
|
|
5.64
|
|
$
|
20,786
|
|
|
Exercisable
|
|
1,322
|
|
|
$
|
28.97
|
|
|
4.49
|
|
$
|
19,733
|
|
|
|
|
Options Outstanding
|
|
Options Exercisable
|
||||||||||||
|
|
|
|
|
Weighted Average
Remaining Contractual Life |
|
Weighted
Average Exercise |
|
Number
|
|
Weighted
Average |
||||||
|
Range of Exercise Prices
|
|
Number
|
|
(years)
|
|
Price
|
|
Exercisable
|
|
Exercise Price
|
||||||
|
$5.00 - $16.25
|
|
345
|
|
|
1.83
|
|
$
|
14.32
|
|
|
345
|
|
|
$
|
14.32
|
|
|
$16.28 - $23.34
|
|
326
|
|
|
4.85
|
|
21.78
|
|
|
326
|
|
|
21.78
|
|
||
|
$23.80 - $32.29
|
|
309
|
|
|
6.28
|
|
31.23
|
|
|
255
|
|
|
31.22
|
|
||
|
$33.38 - $38.99
|
|
303
|
|
|
5.45
|
|
38.27
|
|
|
210
|
|
|
38.37
|
|
||
|
$41.49 - $54.65
|
|
387
|
|
|
8.23
|
|
48.21
|
|
|
118
|
|
|
54.65
|
|
||
|
$55.72 - $55.72
|
|
195
|
|
|
7.93
|
|
55.72
|
|
|
68
|
|
|
55.72
|
|
||
|
|
|
1,865
|
|
|
5.65
|
|
$
|
33.68
|
|
|
1,322
|
|
|
$
|
28.97
|
|
|
|
|
Shares
|
|
Weighted
Average Fair Value |
|||
|
March 26, 2016
|
|
3,163
|
|
|
$
|
26.14
|
|
|
Granted
|
|
947
|
|
|
52.40
|
|
|
|
Vested
|
|
(1,032
|
)
|
|
24.67
|
|
|
|
Forfeited
|
|
(83
|
)
|
|
28.40
|
|
|
|
March 25, 2017
|
|
2,995
|
|
|
34.91
|
|
|
|
Granted
|
|
936
|
|
|
55.79
|
|
|
|
Vested
|
|
(1,077
|
)
|
|
24.79
|
|
|
|
Forfeited
|
|
(85
|
)
|
|
41.09
|
|
|
|
March 31, 2018
|
|
2,769
|
|
|
45.70
|
|
|
|
Granted
|
|
1,416
|
|
|
40.57
|
|
|
|
Vested
|
|
(1,176
|
)
|
|
33.65
|
|
|
|
Forfeited
|
|
(175
|
)
|
|
48.15
|
|
|
|
March 30, 2019
|
|
2,834
|
|
|
$
|
47.99
|
|
|
|
|
Shares
|
|
Weighted
Average Fair Value |
|
Weighted Average
Remaining Contractual Term (years) |
|||
|
Expected to vest
|
|
2,738
|
|
|
$
|
48.07
|
|
|
1.63
|
|
|
|
Year Ended
|
|||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
|
Expected stock price volatility
|
|
38.00-38.14 %
|
|
37.36
|
%
|
|
Risk-free interest rate
|
|
2.62-3.01 %
|
|
1.74
|
%
|
|
Expected term (in years)
|
|
3.00
|
|
3.00
|
|
|
|
|
Shares
|
|
Weighted
Average Fair Value |
|||
|
March 26, 2016
|
|
125
|
|
|
$
|
34.85
|
|
|
Granted
|
|
55
|
|
|
75.58
|
|
|
|
Vested
|
|
—
|
|
|
—
|
|
|
|
Forfeited
|
|
—
|
|
|
—
|
|
|
|
March 25, 2017
|
|
180
|
|
|
$
|
47.30
|
|
|
Granted
|
|
89
|
|
|
47.26
|
|
|
|
Vested
|
|
(70
|
)
|
|
22.00
|
|
|
|
Forfeited
|
|
—
|
|
|
—
|
|
|
|
March 31, 2018
|
|
199
|
|
|
$
|
56.16
|
|
|
Granted
|
|
68
|
|
|
53.13
|
|
|
|
Vested
|
|
—
|
|
|
—
|
|
|
|
Forfeited
|
|
(101
|
)
|
|
43.41
|
|
|
|
March 30, 2019
|
|
166
|
|
|
$
|
62.77
|
|
|
|
|
Shares
|
|
Weighted
Average Fair Value |
|
Weighted Average
Remaining Contractual Term (years) |
|||
|
Expected to vest
|
|
160
|
|
|
$
|
62.91
|
|
|
1.64
|
|
|
|
Facilities Expense
|
|
Facilities Income
|
|
Net Facilities
Commitments |
|
Equipment
and Other Commitments |
|
Total
Commitments |
||||||||||
|
2020
|
|
$
|
14,583
|
|
|
$
|
240
|
|
|
$
|
14,343
|
|
|
$
|
144
|
|
|
$
|
14,487
|
|
|
2021
|
|
13,856
|
|
|
245
|
|
|
13,611
|
|
|
143
|
|
|
13,754
|
|
|||||
|
2022
|
|
13,288
|
|
|
252
|
|
|
13,036
|
|
|
135
|
|
|
13,171
|
|
|||||
|
2023
|
|
12,456
|
|
|
258
|
|
|
12,198
|
|
|
125
|
|
|
12,323
|
|
|||||
|
2024
|
|
12,092
|
|
|
265
|
|
|
11,827
|
|
|
114
|
|
|
11,941
|
|
|||||
|
Thereafter
|
|
35,704
|
|
|
316
|
|
|
35,388
|
|
|
222
|
|
|
35,610
|
|
|||||
|
Total minimum lease payment
|
|
$
|
101,979
|
|
|
$
|
1,576
|
|
|
$
|
100,403
|
|
|
$
|
883
|
|
|
$
|
101,286
|
|
|
|
|
Foreign
Currency |
|
Unrealized Gains
(Losses) on Securities |
|
Actuarial Gains
(Losses) on Defined Benefit Pension Plan |
|
Total
|
||||||||
|
Balance, March 25, 2017
|
|
$
|
(1,302
|
)
|
|
$
|
(31
|
)
|
|
$
|
760
|
|
|
$
|
(573
|
)
|
|
Current period foreign exchange translation
|
|
2,791
|
|
|
—
|
|
|
—
|
|
|
2,791
|
|
||||
|
Current period marketable securities activity
|
|
—
|
|
|
(2,380
|
)
|
|
—
|
|
|
(2,380
|
)
|
||||
|
Current period actuarial gain/loss activity
|
|
—
|
|
|
—
|
|
|
(14,729
|
)
|
|
(14,729
|
)
|
||||
|
Tax effect
|
|
—
|
|
|
750
|
|
|
2,780
|
|
|
3,530
|
|
||||
|
Balance, March 31, 2018
|
|
1,489
|
|
|
(1,661
|
)
|
|
(11,189
|
)
|
|
(11,361
|
)
|
||||
|
Current period foreign exchange translation
|
|
(3,125
|
)
|
|
—
|
|
|
—
|
|
|
(3,125
|
)
|
||||
|
Current period marketable securities activity
|
|
—
|
|
|
2,823
|
|
|
—
|
|
|
2,823
|
|
||||
|
Current period actuarial gain/loss activity
|
|
—
|
|
|
—
|
|
|
13,814
|
|
|
13,814
|
|
||||
|
Tax effect
|
|
—
|
|
|
(592
|
)
|
|
(2,625
|
)
|
|
(3,217
|
)
|
||||
|
Balance, March 30, 2019
|
|
$
|
(1,636
|
)
|
|
$
|
570
|
|
|
$
|
—
|
|
|
$
|
(1,066
|
)
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
U.S.
|
|
$
|
41,980
|
|
|
$
|
91,220
|
|
|
$
|
137,654
|
|
|
Non-U.S.
|
|
51,764
|
|
|
173,879
|
|
|
177,393
|
|
|||
|
|
|
$
|
93,744
|
|
|
$
|
265,099
|
|
|
$
|
315,047
|
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Current:
|
|
|
|
|
|
|
||||||
|
U.S.
|
|
$
|
(7,109
|
)
|
|
$
|
66,082
|
|
|
$
|
28,940
|
|
|
Non-U.S.
|
|
12,428
|
|
|
21,812
|
|
|
7,234
|
|
|||
|
Total current tax provision
|
|
$
|
5,319
|
|
|
$
|
87,894
|
|
|
$
|
36,174
|
|
|
Deferred:
|
|
|
|
|
|
|
||||||
|
U.S.
|
|
5,441
|
|
|
19,309
|
|
|
2,576
|
|
|||
|
Non-U.S.
|
|
(7,007
|
)
|
|
(4,099
|
)
|
|
15,088
|
|
|||
|
Total deferred tax provision
|
|
(1,566
|
)
|
|
15,210
|
|
|
17,664
|
|
|||
|
Total tax provision
|
|
$
|
3,753
|
|
|
$
|
103,104
|
|
|
$
|
53,838
|
|
|
|
|
Fiscal Years Ended
|
|||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
|||
|
U.S. federal statutory rate
|
|
21.0
|
|
|
31.6
|
|
|
35.0
|
|
|
Foreign income taxed at different rates
|
|
(2.9
|
)
|
|
(9.6
|
)
|
|
(8.7
|
)
|
|
Transition tax on deferred foreign income
|
|
(11.8
|
)
|
|
20.3
|
|
|
—
|
|
|
Remeasurement of U.S. deferred tax balance
|
|
(0.1
|
)
|
|
2.3
|
|
|
—
|
|
|
Research and development tax credits
|
|
(6.7
|
)
|
|
(2.5
|
)
|
|
(1.8
|
)
|
|
Stock-based compensation
|
|
(1.0
|
)
|
|
(4.5
|
)
|
|
(7.3
|
)
|
|
Foreign-derived intangible income deduction
|
|
(2.8
|
)
|
|
—
|
|
|
—
|
|
|
Current U.S. tax on foreign earnings
|
|
2.2
|
|
|
0.7
|
|
|
0.1
|
|
|
Change in valuation allowance
|
|
4.4
|
|
|
—
|
|
|
—
|
|
|
Interest related to unrecognized tax benefits
|
|
1.6
|
|
|
—
|
|
|
—
|
|
|
Other
|
|
0.1
|
|
|
0.6
|
|
|
(0.2
|
)
|
|
Effective tax rate
|
|
4.0
|
|
|
38.9
|
|
|
17.1
|
|
|
|
|
March 30,
2019 |
|
March 31,
2018 |
||||
|
Deferred tax assets:
|
|
|
|
|
||||
|
Accrued expenses and allowances
|
|
$
|
4,024
|
|
|
$
|
5,793
|
|
|
Net operating loss carryforwards
|
|
2,940
|
|
|
3,646
|
|
||
|
Research and development tax credit carryforwards
|
|
13,111
|
|
|
12,701
|
|
||
|
Stock-based compensation
|
|
14,667
|
|
|
14,156
|
|
||
|
Other
|
|
1,261
|
|
|
2,402
|
|
||
|
Total deferred tax assets
|
|
$
|
36,003
|
|
|
$
|
38,698
|
|
|
Valuation allowance for deferred tax assets
|
|
(18,588
|
)
|
|
(14,671
|
)
|
||
|
Net deferred tax assets
|
|
$
|
17,415
|
|
|
$
|
24,027
|
|
|
Deferred tax liabilities:
|
|
|
|
|
||||
|
Depreciation and amortization
|
|
$
|
8,913
|
|
|
$
|
9,184
|
|
|
Acquisition intangibles
|
|
8,803
|
|
|
13,427
|
|
||
|
Total deferred tax liabilities
|
|
$
|
17,716
|
|
|
$
|
22,611
|
|
|
Total net deferred tax assets (liabilities)
|
|
$
|
(301
|
)
|
|
$
|
1,416
|
|
|
|
|
March 30,
2019 |
|
March 31,
2018 |
||||
|
Beginning balance
|
|
$
|
55,164
|
|
|
$
|
30,858
|
|
|
Additions based on tax positions related to the current year
|
|
2,204
|
|
|
26,602
|
|
||
|
Reductions based on tax positions related to the prior years
|
|
(17,622
|
)
|
|
(2,296
|
)
|
||
|
Ending balance
|
|
$
|
39,746
|
|
|
$
|
55,164
|
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
Portable Products
|
|
$
|
1,032,049
|
|
|
$
|
1,363,876
|
|
|
$
|
1,373,848
|
|
|
Non-Portable and Other Products
|
|
153,475
|
|
|
168,310
|
|
|
165,092
|
|
|||
|
|
|
$
|
1,185,524
|
|
|
$
|
1,532,186
|
|
|
$
|
1,538,940
|
|
|
|
|
Fiscal Years Ended
|
||||||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
|
March 25,
2017 |
||||||
|
United States
|
|
$
|
26,182
|
|
|
$
|
33,732
|
|
|
$
|
36,024
|
|
|
EMEA
|
|
14,406
|
|
|
15,458
|
|
|
14,791
|
|
|||
|
China
|
|
922,202
|
|
|
1,264,000
|
|
|
1,249,325
|
|
|||
|
Hong Kong
|
|
166,460
|
|
|
162,652
|
|
|
181,283
|
|
|||
|
Japan
|
|
9,210
|
|
|
12,131
|
|
|
11,819
|
|
|||
|
Taiwan
|
|
17,106
|
|
|
13,224
|
|
|
14,426
|
|
|||
|
Other Asia
|
|
18,439
|
|
|
20,044
|
|
|
19,747
|
|
|||
|
Other non-U.S. countries
|
|
11,519
|
|
|
10,945
|
|
|
11,525
|
|
|||
|
Total consolidated sales
|
|
$
|
1,185,524
|
|
|
$
|
1,532,186
|
|
|
$
|
1,538,940
|
|
|
|
|
Fiscal Years Ended
|
||||||
|
|
|
March 30,
2019 |
|
March 31,
2018 |
||||
|
United States
|
|
$
|
126,292
|
|
|
$
|
130,202
|
|
|
EMEA
|
|
39,426
|
|
|
44,339
|
|
||
|
China
|
|
1,682
|
|
|
1,489
|
|
||
|
Japan
|
|
73
|
|
|
115
|
|
||
|
South Korea
|
|
870
|
|
|
1,217
|
|
||
|
Taiwan
|
|
15,349
|
|
|
7,743
|
|
||
|
Other Asia
|
|
1,999
|
|
|
5,444
|
|
||
|
Other non-U.S. countries
|
|
494
|
|
|
605
|
|
||
|
Total consolidated property, plant and equipment, net
|
|
$
|
186,185
|
|
|
$
|
191,154
|
|
|
|
|
Fiscal Year 2019
|
||||||||||||||
|
|
|
1st
Quarter |
|
2nd
Quarter |
|
3rd
Quarter |
|
4th
Quarter |
||||||||
|
Net sales
|
|
$
|
254,483
|
|
|
$
|
366,305
|
|
|
$
|
324,295
|
|
|
$
|
240,441
|
|
|
Gross profit
|
|
124,559
|
|
|
185,119
|
|
|
163,180
|
|
|
124,639
|
|
||||
|
Net income (loss)
|
|
(4,272
|
)
|
|
58,173
|
|
|
29,933
|
|
|
6,157
|
|
||||
|
Basic income (loss) per share
|
|
$
|
(0.07
|
)
|
|
$
|
0.96
|
|
|
$
|
0.50
|
|
|
$
|
0.10
|
|
|
Diluted income (loss) per share
|
|
(0.07
|
)
|
|
0.93
|
|
|
0.49
|
|
|
0.10
|
|
||||
|
|
|
Fiscal Year 2018
|
||||||||||||||
|
|
|
1st
Quarter |
|
2nd
Quarter |
|
3rd
Quarter |
|
4th
Quarter |
||||||||
|
Net sales
|
|
$
|
320,735
|
|
|
$
|
425,537
|
|
|
$
|
482,741
|
|
|
$
|
303,173
|
|
|
Gross profit
|
|
161,716
|
|
|
211,282
|
|
|
235,088
|
|
|
152,630
|
|
||||
|
Net income
|
|
42,912
|
|
|
73,300
|
|
|
33,779
|
|
|
12,004
|
|
||||
|
Basic income per share
|
|
$
|
0.67
|
|
|
$
|
1.16
|
|
|
$
|
0.53
|
|
|
$
|
0.19
|
|
|
Diluted income per share
|
|
0.64
|
|
|
1.10
|
|
|
0.52
|
|
|
0.19
|
|
||||
|
(a)
|
The following documents are filed as part of this Report:
|
|
1.
|
Consolidated Financial Statements
|
|
▪
|
Reports of Ernst & Young LLP, Independent Registered Public Accounting Firm.
|
|
▪
|
Consolidated Balance Sheets as of
March 30, 2019
and
March 31, 2018
.
|
|
▪
|
Consolidated Statements of Income for the fiscal years ended
March 30, 2019
,
March 31, 2018
, and
March 25, 2017
.
|
|
▪
|
Consolidated Statements of Comprehensive Income for the fiscal years ended
March 30, 2019
,
March 31, 2018
, and
March 25, 2017
.
|
|
▪
|
Consolidated Statements of Cash Flows for the fiscal years ended
March 30, 2019
,
March 31, 2018
, and
March 25, 2017
.
|
|
▪
|
Consolidated Statements of Stockholders’ Equity for the fiscal years ended
March 30, 2019
,
March 31, 2018
, and
March 25, 2017
.
|
|
▪
|
Notes to Consolidated Financial Statements.
|
|
2.
|
Financial Statement Schedules
|
|
3.
|
Exhibits
|
|
Number
|
|
Description
|
|
2.1
|
|
|
|
3.1
|
|
|
|
3.2
|
|
|
|
10.1+
|
|
|
|
10.2+
|
|
|
|
10.3+
|
|
|
|
10.4+
|
|
|
|
10.5+
|
|
|
|
10.6+
|
|
|
|
10.7+
|
|
|
|
10.8+
|
|
|
|
10.9+
|
|
|
|
10.10+
|
|
|
|
10.11+
|
|
|
|
10.12+
|
|
|
|
10.13+
|
|
|
|
10.14+
|
|
|
|
10.15+
|
|
|
|
10.16+
|
|
|
|
10.17+
|
|
|
|
10.18+
|
|
|
|
10.19+
|
|
|
|
10.20+
|
|
|
|
10.21+
|
|
|
|
10.22
|
|
|
|
10.23
|
|
|
|
10.24
|
|
|
|
10.25
|
|
|
|
14.1
|
|
|
|
21.1*
|
|
|
|
23.1*
|
|
|
|
24.1*
|
|
Power of Attorney (see signature page).
|
|
31.1*
|
|
|
|
31.2*
|
|
|
|
32.1*
|
|
|
|
32.2*
|
|
|
|
101.INS*
|
|
XBRL Instance Document
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
(1
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on April 29, 2014 (Registration No. 000-17795).
|
|
(2
|
)
|
Incorporated by reference from Registrant’s Report on Form 10-K for the fiscal year ended March 31, 2001, filed with the SEC on June 22, 2001 (Registration No. 000-17795).
|
|
(3
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on September 20, 2013.
|
|
(4
|
)
|
Incorporated by reference from Registration’s Statement on Form S-8 filed with the SEC on August 1, 2006 (Registration No. 000-17795).
|
|
(5
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on October 7, 2010.
|
|
(6
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on August 1, 2007.
|
|
(7
|
)
|
Incorporated by reference to Exhibit A of the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the SEC on June 2, 2015.
|
|
(8
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on September 3, 2014.
|
|
(9
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on September 22, 2014.
|
|
(10
|
)
|
Incorporated by reference from Registrant’s Report on Form 10-K filed with the SEC on May 27, 2015 (Registration No. 000-17795).
|
|
(11
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K filed with the SEC on June 26, 2015.
|
|
(12
|
)
|
Incorporated by reference from Registrant’s Report on Form 10-K filed with the SEC on May 25, 2016 (Registration No. 000-17795).
|
|
(13
|
)
|
Incorporated by reference from Registrant’s Report on Form 8-K with the SEC on July 15, 2016 (Registration No. 000-17795).
|
|
(14
|
)
|
Incorporated by reference from Registrant’s Report on Form 10-K with the SEC on May 30, 2018 (Registration No. 000-17795).
|
|
(15
|
)
|
Incorporated by reference from Registrant’s Statement on Form S-8 filed with the SEC on August 3, 2018 (Registration No. 333-226578).
|
|
|
CIRRUS LOGIC, INC.
|
|
|
|
|
|
|
|
By:
|
/
S
/ T
HURMAN
K. C
ASE
|
|
|
|
Thurman K. Case
|
|
|
|
Vice President, Chief Financial Officer and Chief Accounting Officer
|
|
|
|
May 24, 2019
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ J
ASON
P. R
HODE
|
|
President and Chief Executive Officer
|
|
May 24, 2019
|
|
Jason P. Rhode
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ T
HURMAN
K. C
ASE
|
|
Vice President, Chief Financial Officer and Chief Accounting Officer
|
|
May 24, 2019
|
|
Thurman K. Case
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ J
OHN
C. C
ARTER
|
|
Director
|
|
May 24, 2019
|
|
John C. Carter
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ A
LEX
D
AVERN
|
|
Director
|
|
May 24, 2019
|
|
Alex Davern
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ T
IMOTHY
R. D
EHNE
|
|
Director
|
|
May 24, 2019
|
|
Timothy R. Dehne
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ D
EIRDRE
H
ANFORD
|
|
Director
|
|
May 24, 2019
|
|
Deirdre Hanford
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ A
LAN
R. S
CHUELE
|
|
Director
|
|
May 24, 2019
|
|
Alan R. Schuele
|
|
|
|
|
|
|
|
|
|
|
|
/
S
/ D
AVID
J. T
UPMAN
|
|
Director
|
|
May 24, 2019
|
|
David J. Tupman
|
|
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|